Disease · MONDO_0005083

psoriasis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. psoriasis. Diseases, record MONDO_0005083. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005083

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: psoriasis; Open Targets
Open Targets ID: MONDO_0005083; Open Targets
Other names: OTHER PSORIASIS, Other and unspecified pityriasis, Other psoriasis and similar disorders, Other psoriasis and similar disorders (disorder), Other psoriasis and similar disorders excluding psoriatic arthropathy, PITYRIASIS NEC & NOS, PSORIAS RELATED DIS NEC, PUSTULAR PSORIASIS OF PALMS SOLES, PUSTULOSIS OF PALMS SOLES, Palmoplantaris Pustulosis, Psoriases, Psoriasiform dermatitis, Psoriasis and similar disorders, Psoriasis and similar disorders (disorder), Psoriasis and similar disorders (navigational concept), Psoriasis and similar disorders NOS, Psoriasis and similar disorders NOS (disorder), Pustular Psoriasis of Palms and Soles, Pustulosis Palmaris et Plantaris, Pustulosis of Palms and Soles; Open Targets
Disease Ontology: DOID:8893; Disease Ontology
MeSH: D011565; MeSH
NCI Thesaurus: C3346; NCI Thesaurus
Highest stage of its drugs: Approval, for 46 of its 194 drugs, from ATC, DailyMed, EMA Human Drugs, FDA and PMDA; Open Targets

Drugs194

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CALCIPOTRIENE	CHEMBL1200666	Small molecule	Approval	ATC and DailyMed	72	52	50	Drugs and targets
ETANERCEPT	CHEMBL1201572	Protein	Approval	DailyMed and EMA Human Drugs	49	42	42	Drugs and targets
ADALIMUMAB	CHEMBL1201580	Antibody	Approval	DailyMed and EMA Human Drugs	57	41	40	Drugs and targets
SECUKINUMAB	CHEMBL1743068	Antibody	Approval	DailyMed and EMA Human Drugs	41	39	38	Drugs and targets
METHOTREXATE	CHEMBL34259	Small molecule	Approval	DailyMed and EMA Human Drugs	41	32	32	Drugs and targets
BETAMETHASONE DIPROPIONATE	CHEMBL1200384	Small molecule	Approval	DailyMed	28	26	24	Drugs and targets
APREMILAST	CHEMBL514800	Small molecule	Approval	DailyMed and EMA Human Drugs	28	24	24	Drugs and targets
USTEKINUMAB	CHEMBL1201835	Antibody	Approval	DailyMed and EMA Human Drugs	31	18	17	Drugs and targets
IXEKIZUMAB	CHEMBL1743034	Antibody	Approval	EMA Human Drugs, FDA and PMDA	21	18	18	Drugs and targets
INFLIXIMAB	CHEMBL1201581	Antibody	Approval	DailyMed, EMA Human Drugs and PMDA	24	15	14	Drugs and targets

1 to 10 of 194

See all 194 drugs

Targets187

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	22	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
IL12B	Interleukin-12	8	Interleukin-12 inhibitor; Interleukin-23 inhibitor	Approval	https://conductscience.org/library/genes/3593	Drugs and targets
IL23A	Interleukin-23	8	Interleukin-23 inhibitor	Approval	https://conductscience.org/library/genes/51561	Drugs and targets
JAK1	Janus Kinase (JAK)	7	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK1 inhibitor	Phase 3	https://conductscience.org/library/genes/3716	Drugs and targets
VDR	Vitamin D3 receptor	7	Vitamin D receptor agonist	Approval	https://conductscience.org/library/genes/7421	Drugs and targets
IL17A	Interleukin-17A	6	Interleukin 17A binding agent; Interleukin 17A inhibitor	Approval	https://conductscience.org/library/genes/3605	Drugs and targets
TYK2	Janus Kinase (JAK)	6	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase TYK2 negative allosteric modulator	Approval	https://conductscience.org/library/genes/7297	Drugs and targets
JAK2	Janus Kinase (JAK)	5	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK2 inhibitor	Phase 3	https://conductscience.org/library/genes/3717	Drugs and targets
TNF	Tumor necrosis factor	5	TNF-alpha inhibitor	Approval	https://conductscience.org/library/genes/7124	Drugs and targets
GLP1R	Glucagon-like peptide 1 receptor	3	Glucagon-like peptide 1 receptor agonist	Phase 3	https://conductscience.org/library/genes/2740	Drugs and targets

1 to 10 of 187

See all 187 targets

Trials495

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 10 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02409667	Plaque Psoriasis Efficacy and Safety With Secukinumab	Phase 3	16,487	2019-05-13	Plaque Psoriasis	SECUKINUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT01708629	Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects	Phase 3	1,881	2020-01-03	Plaque Psoriasis	BRODALUMAB, USTEKINUMAB	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT02752776	A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis.	Phase 4	1,660	2019-09-25	Plaque Psoriasis	SECUKINUMAB	Its record names the disease	ClinicalTrials.gov
NCT01358578	Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis	Phase 3	1,306	2015-09-23	Chronic Plaque Psoriasis	ETANERCEPT, SECUKINUMAB	Its record names the disease	ClinicalTrials.gov
NCT02513550	A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis	Phase 3	1,257	2018-04-18	Plaque Psoriasis	IXEKIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT01544595	Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab	Phase 3	1,147	2018-12-20	Moderate to Severe Plaque-type Psoriasis	SECUKINUMAB	Its record names the disease	ClinicalTrials.gov
NCT02826603	Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis	Phase 3	1,114	2019-07-09	Plaque Psoriasis	SECUKINUMAB, USTEKINUMAB	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT01729754	A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)	Phase 3	1,090	2018-06-27	Plaque Psoriasis	TILDRAKIZUMAB	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT00760669	An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Participants		1,061	2013-08-12	Spondylitis, Ankylosing, Arthritis, Rheumatoid, Psoriasis, Arthritis, Psoriatic	INFLIXIMAB	Its record names the disease	ClinicalTrials.gov
NCT03573323	A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis	Phase 4	1,027	2020-07-28	Plaque Psoriasis	GUSELKUMAB, IXEKIZUMAB	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov

1 to 10 of 495

See all 495 trials

Comparisons in its trials192

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Treatment Period 2: Group 1 vs Treatment Period 2: Group 2: Maintenance of PASI 90 Response at Week 52 in Participants With a PASI 90 Response at Week 24	552 of 644	496 of 662	1,306	NCT02409667	Trial comparisons
Secukinumab 300mg (2 x 150 mg) vs Ustekinumab 2 x 45mg or 90mg: Participants Who Achieved Psoriasis Area and Severity Index (PASI) 100 Response at Week 12	210 of 550	111 of 552	1,102	NCT02826603	Trial comparisons
Secukinumab 300mg (2 x 150 mg) vs Ustekinumab 2 x 45mg or 90mg: Participants With IGA Mod 2011 0 or 1 at 16 Weeks	432 of 550	326 of 552	1,102	NCT02826603	Trial comparisons
Secukinumab 300mg (2 x 150 mg) vs Ustekinumab 2 x 45mg or 90mg: Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 4	221 of 550	90 of 552	1,102	NCT02826603	Trial comparisons
Secukinumab 300mg (2 x 150 mg) vs Ustekinumab 2 x 45mg or 90mg: Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 16	506 of 550	441 of 552	1,102	NCT02826603	Trial comparisons
Secukinumab 300mg (2 x 150 mg) vs Ustekinumab 2 x 45mg or 90mg: Participants Who Achieved Psoriasis Area and Severity Index (PASI) 100 Response at Week 16	250 of 550	147 of 552	1,102	NCT02826603	Trial comparisons
Secukinumab 300mg (2 x 150 mg) vs Ustekinumab 2 x 45mg or 90mg: Participants Who Achieved Psoriasis Area and Severity Index (PASI) 75 Response at Week 12	484 of 550	409 of 552	1,102	NCT02826603	Trial comparisons
Secukinumab 300mg (2 x 150 mg) vs Ustekinumab 2 x 45mg or 90mg: Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 16	423 of 550	299 of 552	1,102	NCT02826603	Trial comparisons
Secukinumab 300mg (2 x 150 mg) vs Ustekinumab 2 x 45mg or 90mg: Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 12	366 of 550	265 of 552	1,102	NCT02826603	Trial comparisons
Secukinumab 300mg (2 x 150 mg) vs Ustekinumab 2 x 45mg or 90mg: Participants With IGA Mod 2011 0 or 1 at Week 12	397 of 550	306 of 552	1,102	NCT02826603	Trial comparisons

1 to 10 of 192

See all 192 comparisons in its trials

Papers from its trials348

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41800601	RESULT	3	PubMed
41580158	RESULT	2	PubMed
41359217	RESULT	2	PubMed
41060492	RESULT	3	PubMed
39578348	RESULT	3	PubMed
38588819	RESULT	1	PubMed
38300408	RESULT	1	PubMed
37953417	RESULT	1	PubMed
37950894	RESULT	2	PubMed
37908308	RESULT	1	PubMed

1 to 10 of 348

See all 348 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005083

GET https://conductscience.org/api/diseases/v1/MONDO_0005083/drugs?page=2

API reference For AI assistants